Jacobs & Co. CA Has $7.56 Million Stock Position in Abbott Laboratories (NYSE:ABT)

Jacobs & Co. CA lessened its holdings in Abbott Laboratories (NYSE:ABT) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,720 shares of the healthcare product maker’s stock after selling 570 shares during the quarter. Jacobs & Co. CA’s holdings in Abbott Laboratories were worth $7,564,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Altshuler Shaham Ltd bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $28,000. Cornerstone Planning Group LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $28,000. Halpern Financial Inc. acquired a new position in Abbott Laboratories in the third quarter valued at approximately $26,000. CGC Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 2nd quarter valued at $32,000. Finally, FWL Investment Management LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.8 %

Abbott Laboratories stock opened at $113.47 on Thursday. The stock’s 50 day simple moving average is $115.14 and its two-hundred day simple moving average is $106.37. The firm has a market cap of $196.89 billion, a PE ratio of 34.81, a P/E/G ratio of 2.65 and a beta of 0.75. Abbott Laboratories has a 12 month low of $89.67 and a 12 month high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, hitting the consensus estimate of $1.19. The business had revenue of $10.24 billion during the quarter, compared to the consensus estimate of $10.19 billion. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.03 EPS. Analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a yield of 1.94%. Abbott Laboratories’s payout ratio is presently 67.48%.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 42,500 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the transaction, the executive vice president now owns 65,027 shares of the company’s stock, valued at approximately $7,315,537.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the transaction, the executive vice president now directly owns 78,704 shares in the company, valued at approximately $9,444,480. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,435 shares of company stock worth $6,451,298. Insiders own 1.10% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Citigroup lifted their price target on Abbott Laboratories from $123.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Royal Bank of Canada restated an “outperform” rating and set a $128.00 price target on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Barclays upped their price objective on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Finally, Raymond James increased their price target on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.